3D bioprinting News
-
VIVAX BIO and 3D Bioprinting Solutions World’s First To Print Living Tissue in Space
VIVAX BIO, 3D Bioprinting Solutions biotechnology laboratory and INVITRO, a leading medical company, announced a successful completion of the first stage of the Magnetic 3D Bioprinter space experiment. On December 3, 2018, the Organ.Aut bioprinter was delivered to the ISS on board the Soyuz MS-11 manned spacecraft. For the first time on orbit, cosmonaut-researcher Oleg Kononenko printed human ...
-
3D Bioprinting Solutions and URSC Cooperation Agreement - The Development of a Bioprinter for Space Applications
3D Bioprinting Solutions, a resident company of Skolkovo Innovation Center has entered into a cooperation agreement with URSC (Unified Rocket and Space Corporation, a member of ROSCOSMOS State Corporation), aiming to create a unique bioprinter capable of magnetic biofabrication of tissue and organ constructs in zero-gravity at the International Space Station (ISS). It was signed by the URSC ...
-
BIOLIFE4D Becomes First U.S. Company to Successfully Demonstrate Ability to 3D Bioprint a Mini Human Heart
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has successfully demonstrated its ability to 3D bioprint a mini human heart, a significant step toward its goal of producing a full-sized human heart viable for transplant. The scientific milestone was accomplished at the Company’s research facility at ...
By BIOLIFE4D
-
VIVAX BIO, 3D Bioprinting Solutions, and partners complete the first cultured meat biofabrication experiment on board the ISS.
3D Bioprinting Solutions biotechnology laboratory, Meal Source Technologies, as well as Aleph Farms and Finless Foods, are proud to announce successful result of the joint project which involved magnetic biofabrication of bovine, mummichog and rabbit myoblast/fibroblast constructs in order to lay the groundwork for renewable protein sources for long term manned missions. Additionally, results of ...
-
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Following Significant Scientific Achievement
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, announced it has modified its Regulation A+ (Mini-IPO) offering following a successful September re-launch. BIOLIFE4D has raised more than $3M in equity crowdfunding investments since February of 2018. BIOLIFE4D’s modified Regulation A+ offering will allow the company to ...
By BIOLIFE4D
-
ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting ...
-
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear (auricle) to be smaller than typical, misshapen, and sometimes ...
-
CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
By CELLINK
-
Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
By CELLINK
-
BIOLIFE4D Names Pharmaceutical Veteran Kate Lewis as President
BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company. She joined BIOLIFE4D full time in early 2019 in a market and business development role before being elevated as the first female executive in Company history. Lewis brings more than 25 years of experience and ...
By BIOLIFE4D
-
Stefan Blomsterberg appointed as new CEO of Cellink Bioprinting AB
Stefan Blomsterberg has been appointed as the new CEO of CELLINK. Cecilia Edebo, current CEO, requested earlier this year to resign from her position to pursue a new career opportunity outside the BICO Group. At the time of her resignation, a recruitment process was initiated which concluded in the appointment of Stefan Blomsterberg. Stefan Blomsterberg (born 1964) brings 20+ years of experience ...
By CELLINK
-
3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear ...
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior printability, mechanical stability, and ...
By CELLINK
-
3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer is the former CEO and Chairman of Celgene and currently serves as Chairman of Teva Pharmaceuticals. Dr. Slawin, Founder and Managing Partner of Rapha Capital Management, previously founded ...
-
CELLINK and Atelerix team up to enable the shipping at room temperature of fragile 3D bioprinted constructs by the world’s bioprinting community
CELLINK and Atelerix announced today a partnership to bring to market Atelerix’s portfolio of innovative hydrogel biological encapsulation products, which preserve fragile biological samples for shipping at room temperature. Conventional shipping methods often involve storing cells and tissues in liquid nitrogen or dry ice, which requires a freeze-thaw process notorious for ...
By Atelerix Ltd
-
Matexcel Provides Expansive Array of Bio-ink Products for Different Applications
Matexcel, a leading innovator in advanced materials and bioengineering, today announced its diverse portfolio of bio-ink products, empowering researchers across various fields to unlock the potential of 3D bioprinting. This comprehensive range, featuring tailored bio-inks for specific applications, paves the way for revolutionary advancements in regenerative medicine, drug discovery, and beyond. ...
By Matexcel
-
VIVAX BIO on a mission for COVID-19 drug discovery
Following its aspiring mission “Creating future opportunities” the biotechnological research laboratory “3D Bioprinting Solutions” and VIVAX BIO take an active part in pharmacological studies of various antiviral drugs. During the most difficult challenge in recent healthcare history cell biologists from the laboratory's research team began working with leading virologists ...
-
Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...
-
Aspect Biosystems Appoints Ray Smith as Chief Financial Officer
Aspect Biosystems, a biotechnology company developing bioprinted therapeutics, is pleased to announce the appointment of Ray Smith as its new Chief Financial Officer. In his role as Chief Financial Officer, Ray will assume leadership responsibilities for financial management and business operations. “Since leaving the University of British Columbia’s campus and launching our ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you